Advanced Patient Monitoring
NON-INVASIVE, PRECISE, INDIVIDUALISED
Fully non-invasive, accurate and reliable, Baxter’s approach to advanced patient monitoring enables clinicians to respond to ever-changing patient physiology and manage patient care accordingly.1 In keeping with Baxter's mission to save and sustain lives, the objective is to give clinicians the data they need to personalise and optimise patient therapy.
PATIENT MONITORING AND FLUID MANAGEMENT
As part of our fluid management therapy suite, our patient monitoring technology is ultimately intended to guide clinicians in delivering the right Baxter solutions at the right time.
PERSONALISED FLUID MANAGEMENT USING THE NON-INVASIVE STARLING SYSTEM
Our 100% non-invasive Starling Fluid Management Monitoring System supports individualised therapy for haemodynamically unstable patients throughout the hospital setting, using dynamic assessment of a patient’s fluid responsiveness to personalise fluid therapy. The Starling system employs patented Bioreactance technology to provide accurate real-time, continuous, central-flow-based measurements of a variety of haemodynamic parameters.1
SV STARLING Monitor — Non-invasive haemodynamic monitoring system.
Intended purpose: The Starling SV system, with NIBP and SpO2 functionality, is intended for professional use in healthcare facilities. It is a portable non-invasive haemodynamic cardiac output monitor. It monitors and displays a patient's cardiac output (CO) in l/min with a non-invasive blood pressure (NIBP) function that non-invasively measures and displays blood pressure (diastolic, systolic and mean) and heart rate, and an SpO2 function that non-invasively measures and displays blood oxygen saturation (SpO2). The device displays the corresponding haemodynamic parameters based on measurements or measurement calculations already incorporated in the Starling SV.
Class IIa device. Notified body: MEDCERT - Germany (CE 0482).
Please refer to the instructions for use for information necessary for proper use.
Carefully read the instructions in the package insert.
Date of revision: 31 March 2020.
Baxter, Bioreactance and Starling are trademarks of Baxter International Inc. or its subsidiaries.